Lupin: Look beyond the short-term concerns

Strong product approval rate in the US and mega launches on exclusivity basis are key positives

Ujjval Jauhari 

News flow around US product approvals and launches remain strong for Lupin. In the past few days, it has received one approval for launch on exclusivity for a Bowel preparation kit. Also, it has launched a scalp treatment and a dermatology drug in the US. Besides, it has also entered into a marketing agreement in Japan to exclusively distribute and promote extended-release tablets of schizophrenia drug. The tie-up in Japan will boost revenue from the world’s second largest drug market, which contributes 10 per cent to Lupin’s top line and the launch of Bowel kit can garner ...

TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH

Key stories on business-standard.com are available to premium subscribers only.

LOGIN

EMAIL / USER NAME
PASSWORD
REMEMBER ME Forgot password?
LOGIN

Not a member yet ? Resister Now

Connect using any below

  • Don't lose the opportunity of saving $26.77 per month
  • Don't lose the opportunity of saving $26.77 per month
Total Amount
Rs. 0.00
To proceed, kindly select a subscription package

WHAT YOU GET

On Business Standard Digital

  • Access your subscription from anywhere. Be it your computer, tablet or smartphone using a browser or the App, Your Choice.
  • Access to exclusive content, features, opinions and comment, hand-picked by our editors, just for you.
  • Pick your 5 favourite companies. Get all the news upates at the end of each day through E-Mail.
  • Pick the industry that you want to track. And get a daily news letter specific to that industry. Cut out the clutter.
  • And stay on top of your investments. Track stock prices in your portfolio
  • Access 18 years of archival data

On Digital

  • Seamless access to WSJ.com with your Business Standard digital account.
  • Experience the best of the Journal's reporting, video and interactive features.
  • Read about the people and events shaping business, finance, technology, politics, technology and culture.
  • Stay informed with newsletters - an easy way to get WSJ content straight to your inbox - making life easier on your busiest days.
  • More business executives read the Journal globally than any other publication.
*Note :
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital

Lupin: Look beyond the short-term concerns

Strong product approval rate in the US and mega launches on exclusivity basis are key positives

News flow around US product approvals and launches remains strong for Lupin. In the last few days, Lupin has received one approval for launch on exclusivity for a Bowel preparation kit and has also launched a scalp treatment as well as a dermatology drug in the US. Besides, it has also entered into a marketing agreement in Japan to exclusively distribute and promote extended-release tablets of schizophrenia drug. The tie up in Japan will boost revenue from the world's second largest drug market, which contributes about 10 per cent to Lupin's topline, while the launch of Bowel kit can garner $30 million during exclusivity. The approvals for new launches have caught pace post Lupin got its Goa plant cleared by the US FDA; 11 approvals in December quarter and more are expected. However, the stock has remained range-bound even after good December quarter performance. One reason could be that these gains may not be as visible in revenue and profits of Lupin in the immediate term given the . News flow around US product approvals and launches remain strong for Lupin. In the past few days, it has received one approval for launch on exclusivity for a Bowel preparation kit. Also, it has launched a scalp treatment and a dermatology drug in the US. Besides, it has also entered into a marketing agreement in Japan to exclusively distribute and promote extended-release tablets of schizophrenia drug. The tie-up in Japan will boost revenue from the world’s second largest drug market, which contributes 10 per cent to Lupin’s top line and the launch of Bowel kit can garner ... image
Business Standard
177 22